Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 93 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Oct 3, 2026 to Sep 30, 2027 Show 4 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description revised
    • Site details revised at 7 of 14 sites
  2. Study sites revised (14)v92
  3. Study completion date: Oct 3, 2025 to Oct 3, 2026v91
  4. 2 versions Re-verified since Mar 26, 2025, no change to tracked fieldsv89-v90
  5. Study completion date: Sep 22, 2024 to Oct 3, 2025v88
Show 44 earlier versionsHide 44 earlier versions
  1. 3 versions Re-verified since Feb 21, 2024, no change to tracked fieldsv85-v87
  2. Results first posted: Feb 20, 2024v84 Show 4 more changesShow less
    • Start date: Dec 7, 2016 to May 8, 2017
    • Primary endpoint revised
    • Study completion date: Feb 24, 2024 to Sep 22, 2024
    • Secondary endpoints: 6 to 5
  3. Enrollment target: estimated 47 to confirmed 11
    • Primary completion date changed from estimate of Dec 31, 2023 to Aug 19, 2022
    • Study completion date: Dec 31, 2023 to Feb 24, 2024
    v83
  4. Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023v82
  5. Trial status: Suspended to Active, Not Recruitingv81
  6. 3 versions Re-verified since Jun 7, 2022, no change to tracked fieldsv78-v80
  7. Trial status: Recruiting to Suspended Sponsor's reason: Scheduled Interim Monitoring
    • Primary completion date: Dec 31, 2021 to Dec 31, 2022
    • Study completion date: Dec 31, 2022
    • Site details revised at 14 of 14 sites
    v77
  8. Site details revised at 1 of 14 sitesv76
  9. Site details revised at 2 of 14 sitesv75
  10. Re-verified, no change to tracked fieldsv74
  11. Site details revised at 2 of 14 sitesv73
  12. Re-verified, no change to tracked fieldsv72
  13. Study sites: 12 to 14v71
  14. Primary completion date: Dec 31, 2020 to Dec 31, 2021v70
  15. Site details revised at 1 of 12 sitesv69
  16. 2 versions Re-verified since Sep 22, 2020, no change to tracked fieldsv67-v68
  17. Site details revised at 3 of 12 sitesv66
  18. Re-verified, no change to tracked fieldsv65
  19. Eligibility criteria expanded, about 24 words
    • Study description shortened, about 32 words
    • Site details revised at 1 of 12 sites
    v64
  20. Re-verified, no change to tracked fieldsv63
  21. Site details revised at 1 of 12 sitesv62
  22. Re-verified, no change to tracked fieldsv61
  23. Trial status: Suspended to Recruiting
    • Site details revised at 12 of 12 sites
    v60
  24. Primary completion date: Dec 31, 2019 to Dec 31, 2020v59
  25. Re-verified, no change to tracked fieldsv58
  26. Trial status: Recruiting to Suspended Sponsor's reason: Other - Amendment required to lower treatment dosage
    • Site details revised at 12 of 12 sites
    v57
  27. Re-verified, no change to tracked fieldsv56
  28. Primary completion date: Aug 1, 2019 to Dec 31, 2019
    • Study completion date: Aug 1, 2019 to not stated
    v55
  29. Study sites: 11 to 12v54
  30. Re-verified, no change to tracked fieldsv53
  31. Trial status: Suspended to Recruiting
    • Site details revised at 11 of 11 sites
    v52
  32. Re-verified, no change to tracked fieldsv51
  33. Study sites revised (11)v50
  34. Re-verified, no change to tracked fieldsv49
  35. Trial status: Recruiting to Suspended Sponsor's reason: Scheduled Interim Monitoring
    • Site details revised at 11 of 11 sites
    v48
  36. Study sites: 10 to 11v47
  37. Site details revised at 3 of 10 sitesv46
  38. Trial status: Suspended to Recruiting
    • Study completion date: Aug 1, 2019
    • Site details revised at 10 of 10 sites
    v45
  39. Re-verified, no change to tracked fieldsv44
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases). Ropidoxuridine may help whole brain radiation therapy work better by making cancer cells more sensitive to the radiation therapy.
Trial Details
NCT Number NCT02993146
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
Related terms Brain Neoplasms, Hematologic Neoplasms
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov